ExpreS2ion Biotech Holding AB (EXPRS2) — Working Capital to Net Assets Ratio
ExpreS2ion Biotech Holding AB (EXPRS2) has a Working Capital to Net Assets ratio of 82.0% as of December 2025. Working capital of Skr29.27 Million (current assets of Skr57.53 Million minus current liabilities of Skr28.26 Million) is measured against net assets of Skr35.69 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See ExpreS2ion Biotech Holding AB (EXPRS2) net asset quality to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
ExpreS2ion Biotech Holding AB Working Capital to Net Assets (2013–2025)
This chart shows how ExpreS2ion Biotech Holding AB's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of December 2025, the ratio stands at 82.0%, reflecting working capital of Skr29.27 Million against net assets of Skr35.69 Million SEK. Check how tangible is ExpreS2ion Biotech Holding AB's equity to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for ExpreS2ion Biotech Holding AB (2013–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for ExpreS2ion Biotech Holding AB from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see how much is ExpreS2ion Biotech Holding AB worth.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 82.0% | Skr29.27 Million | Skr35.69 Million | Skr57.53 Million | Skr28.26 Million | ▼ -6.0 pp |
| 2024 | 88.1% | Skr56.73 Million | Skr64.42 Million | Skr94.98 Million | Skr38.25 Million | ▲ +0.4 pp |
| 2023 | 87.6% | Skr57.28 Million | Skr65.36 Million | Skr68.67 Million | Skr11.38 Million | ▼ -9.6 pp |
| 2022 | 97.3% | Skr100.52 Million | Skr103.33 Million | Skr131.94 Million | Skr31.43 Million | ▼ -1.8 pp |
| 2021 | 99.0% | Skr139.00 Million | Skr140.35 Million | Skr146.46 Million | Skr7.46 Million | ▼ -0.6 pp |
| 2020 | 99.7% | Skr94.25 Million | Skr94.55 Million | Skr112.46 Million | Skr18.21 Million | ▼ -92.9 pp |
| 2019 | 192.6% | Skr-2.08 Million | Skr-1.08 Million | Skr10.14 Million | Skr12.21 Million | ▲ +122.9 pp |
| 2018 | 69.7% | Skr5.79 Million | Skr8.30 Million | Skr10.83 Million | Skr5.04 Million | ▲ +14.9 pp |
| 2017 | 54.8% | Skr3.69 Million | Skr6.74 Million | Skr6.05 Million | Skr2.36 Million | ▼ -8.9 pp |
| 2016 | 63.7% | Skr8.21 Million | Skr12.88 Million | Skr11.79 Million | Skr3.58 Million | ▼ -43.7 pp |
| 2015 | 107.4% | Skr-6.46 Million | Skr-6.01 Million | Skr3.64 Million | Skr10.10 Million | ▲ +43.5 pp |
| 2014 | 63.9% | Skr1.50 Million | Skr2.35 Million | Skr4.63 Million | Skr3.13 Million | ▲ +19.0 pp |
| 2013 | 45.0% | Skr868.07K | Skr1.93 Million | Skr3.04 Million | Skr2.18 Million | — |